SCHEMBL416093

SCHEMBL416093

CC(C)[Si](C(C)C)(C(C)C)n1cc(CCl)c2cccnc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.35
ELANE P08246 3/20 0.34
PDE4A P27815 3/20 0.32
PDE4B Q07343 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
KDM4E B2RXH2 3/20 0.32
NPC1 O15118 2/20 0.32
HTT P42858 2/20 0.32
RAB9A P51151 2/20 0.32
MAPT P10636 1/20 0.32
HTR6 P50406 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
FEN1 P39748 1/20 0.31
KCNH2 Q12809 1/20 0.30
LMNA P02545 1/20 0.30
GAA P10253 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411033 0.83 ELANE (0.36) ELANEKDM4EHTR6ALDH1A1SMN1; SMN2
SCHEMBL12147051 0.83 KDM4E (0.46) L3MBTL1PDE4AKDM4ENPC1HTT
SCHEMBL12500888 0.81 ELANE (0.39) L3MBTL1ELANEPDE4APDE4BPDE4C
SCHEMBL15091644 0.81 CTSB (0.40) L3MBTL1ELANEPDE4AKDM4EHTT
SCHEMBL413117 0.79 L3MBTL1 (0.40) L3MBTL1HTR6ALDH1A1
SCHEMBL415786 0.79 HDAC3 (0.38) L3MBTL1PDE4ANPC1HTTRAB9A
SCHEMBL1266638 0.79 GAA (0.35) L3MBTL1KDM4EMAPTKCNH2LMNA
SCHEMBL12251688 0.78 CSF1R (0.37) L3MBTL1KDM4EPTGDR2ALDH1A1KCNH2
SCHEMBL415255 0.77 ELANE (0.42) L3MBTL1ELANEPDE4APDE4BPDE4C
SCHEMBL414164 0.77 ELANE (0.42) L3MBTL1ELANEPDE4AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2019-08-29 US disclosed
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2018-04-26 US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 US disclosed
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR PLEXXIKON INC. 2017-08-31 US disclosed
US-9487515-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2016-11-08 US disclosed
US-9487515-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2016-11-08 US disclosed
EP-3088400-A1 PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON INC. (US) 2016-11-02 EP disclosed
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2016-06-23 US disclosed
EP-2395004-B1 Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors PLEXXIKON INC (US) 2016-01-20 EP disclosed
US-9169250-B2 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC. (US) 2015-10-27 US disclosed
US-20090105297-A1 Compounds Modulating C-Kit Activity PLEXXIKON INC 2009-04-23 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor PLEXXIKON INC 2009-03-19 US disclosed
US-7498342-B2 Compounds modulating c-kit activity PLEXXIKON, INC. (US) 2009-03-03 US disclosed
EP-1893612-A1 PYRROLO [2, 3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2008-03-05 EP disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 US disclosed
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor PLEXXIKON, INC. 2007-02-08 US disclosed
WO-2007002433-A1 PYRROLO [2, 3-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS PLEXXIKON, INC. (US) 2007-01-04 WO disclosed
US-20060058340-A1 Compounds modulating c-kit activity PLEXXIKON INC. 2006-03-16 US disclosed
US-20060058339-A1 Compounds modulating c-kit activity and uses therefor PLEXXIKON, INC. 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247370-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 L3MBTL1 3620/4885ELANE 1793/4885PDE4A 1199/4885
US-20090076046-A1 Compounds modulating c-fms and/or c-kit activity and uses therefor KIT, FLT3, FLT1 L3MBTL1 3620/4885ELANE 1793/4885PDE4A 1199/4885
US-20180111929-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 L3MBTL1 794/4885ELANE 3585/4885PDE4A 826/4885
US-20060058340-A1 Compounds modulating c-kit activity KIT, CDC7, CDK7 L3MBTL1 2764/4885ELANE 4050/4885PDE4A 977/4885
US-20160176865-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR MAP3K20, MAP3K13, MAP3K8 L3MBTL1 794/4885ELANE 3585/4885PDE4A 826/4885
US-20090105297-A1 Compounds Modulating C-Kit Activity KIT, CDC7, CDK7 L3MBTL1 2764/4885ELANE 4050/4885PDE4A 977/4885
US-20190263800-A1 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR KIT, FLT3, FLT1 L3MBTL1 3499/4885ELANE 2195/4885PDE4A 1302/4885
US-20060058339-A1 Compounds modulating c-kit activity and uses therefor KIT, APC, RET L3MBTL1 3188/4885ELANE 4188/4885PDE4A 993/4885
US-20070032519-A1 Compounds modulating c-kit and c-fms activity and uses therefor KIT, FLT3, FLT1 L3MBTL1 3488/4885ELANE 2016/4885PDE4A 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.